Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PD-1/CTLA-4 Antibody + Radiotherapy in dMMR/MSI-H Gastric Cancer
NCT07053332Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in gastric adenocarcinoma and esophagogastric junction adenocarcinoma (GEJA), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Pathological Complete Response Rate and Treatment-related adverse reactions. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT07053332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053332.